Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
| Status: | Archived |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
| End Date: | September 2015 |
BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study
Ixabepilone will be given IV weekly for 12 weeks prior to prostatectomy for patients with
localized, high risk prostate cancer. The objective of this study is to determine if
ixabepilone can shrink prostate cancer prior to prostatectomy.
Ixabepilone will be given IV weekly for 12 weeks, in an intensive 20 mg/m2/week schedule,
prior to prostatectomy for patients with localized, high risk prostate cancer. The objective
of this study is to determine the PSA response and pathologic complete response of weekly
ixabepilone.
We found this trial at
1
site
Click here to add this to my saved trials
